Epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies in Spain, 1997–2024

Clicks: 11
ID: 333813
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #324 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To define the epidemiology, autoimmune overlap and in-hospital outcomes of idiopathic inflammatory myopathies (IIM) in Spain, separating true IIM from the symptomatic-myopathy code (G73.7), and to identify predictors of mortality and intensive-care (ICU) admission. METHODS: Population-based analysis of the Spanish hospital-discharge registries (CMBD and RAE-CMBD, 1997-2024). Rates are hospitalization rates, not incidence or prevalence. True IIM comprised the DM/PM group (dermatomyositis, polymyositis and paraneoplastic DM codes), immune-mediated necrotizing myopathy/other (IMNM/Other) and inclusion body myositis (IBM). Estimates were verified against patient-clustered standard errors. RESULTS: Of 36 732 episodes (8053 patients in 2016-2024, 9162 earlier), 34 228 (93.2%) were true IIM (DM/PM group 84.0%: 61.4% DM-coded, 35.7% PM-coded, 2.9% paraneoplastic; IMNM/Other 13.7%, IBM 2.4%). Hospitalization rose from 1.67 to 4.24 per 100 000/year, confined to ages ≥60. Coexisting autoimmune disease occurred in 13.7% (about one in seven). Mortality was 6.1% and stable. Predictors of death were advancing age (adjusted OR up to 7.97), malignancy, heart failure, interstitial lung disease (ILD), dysphagia and chronic kidney disease (C-statistic 0.77); ICU admission fell in the very elderly (OR 0.21), indicating ceiling-of-care de-escalation. Apparent protective effects of COPD and diabetes reflected collider bias. Within the DM/PM group, 29.4% were coded as polymyositis (M33.2), with more ILD, overlap and antisynthetase features but less malignancy, declining from 40% to 27%. CONCLUSION: IIM hospitalizations doubled over 28 years, driven by IMNM recognition and ageing, with outcomes governed by acute complications and comorbidity rather than subtype. Symptomatic myopathy should be analysed separately and paraneoplastic dermatomyositis unified with idiopathic DM.
Reference Key
openalex_W7223449715 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jorge Álvarez Troncoso, Albert Selva-O'Callaghan, Albert Gil‐Vila, Ernesto Trallero Araguás, Iago Pinal‐Fernandez, María Casal-Domínguez, Jose César Milisenda, Ana Matas-García, Samuel Díaz Planellas, Mario Martín‐Portugués, Víctor Moreno‐Torres
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag593
URL
https://doi.org/10.1093/rheumatology/keag593
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.